|
US510087A
(en)
|
|
1893-12-05 |
|
Method of securing suspension-loops to the ends of hammock-bodies |
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US3896111A
(en)
*
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
|
USRE30985E
(en)
*
|
1978-01-01 |
1982-06-29 |
|
Serum-free cell culture media
|
|
FR2413974A1
(fr)
|
1978-01-06 |
1979-08-03 |
David Bernard |
Sechoir pour feuilles imprimees par serigraphie
|
|
JPS54109494A
(en)
*
|
1978-02-16 |
1979-08-28 |
Teikoku Hormone Mfg Co Ltd |
Method of measuring antigennantibody reaction
|
|
US4265814A
(en)
*
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
|
US4307016A
(en)
*
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4256746A
(en)
*
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
|
JPS55164687A
(en)
*
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS5566585A
(en)
*
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
|
JPS55162791A
(en)
*
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55164686A
(en)
*
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
|
JPS5645483A
(en)
*
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
|
EP0028683A1
(en)
*
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
|
JPS5645485A
(en)
*
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
|
US4419446A
(en)
*
|
1980-12-31 |
1983-12-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant DNA process utilizing a papilloma virus DNA as a vector
|
|
US4313946A
(en)
*
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
|
JPS57192389A
(en)
*
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
|
US4601978A
(en)
|
1982-11-24 |
1986-07-22 |
The Regents Of The University Of California |
Mammalian metallothionein promoter system
|
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4675187A
(en)
|
1983-05-16 |
1987-06-23 |
Bristol-Myers Company |
BBM-1675, a new antibiotic complex
|
|
US4767704A
(en)
*
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
|
US4683203A
(en)
|
1984-04-14 |
1987-07-28 |
Redco N.V. |
Immobilized enzymes, processes for preparing same, and use thereof
|
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
|
GB8426467D0
(en)
|
1984-10-19 |
1984-11-28 |
Technology Licence Co Ltd |
Monoclonal antibodies
|
|
US4970198A
(en)
|
1985-10-17 |
1990-11-13 |
American Cyanamid Company |
Antitumor antibiotics (LL-E33288 complex)
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
|
US4676980A
(en)
*
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5079233A
(en)
|
1987-01-30 |
1992-01-07 |
American Cyanamid Company |
N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
|
|
WO1988007089A1
(en)
*
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
US5053394A
(en)
*
|
1988-09-21 |
1991-10-01 |
American Cyanamid Company |
Targeted forms of methyltrithio antitumor agents
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
IE61148B1
(en)
|
1988-03-10 |
1994-10-05 |
Ici Plc |
Method of detecting nucleotide sequences
|
|
US20030232010A2
(en)
*
|
1988-03-29 |
2003-12-18 |
Immunomedics, Inc. |
Improved cytotoxic therapy
|
|
AU632065B2
(en)
|
1988-09-23 |
1992-12-17 |
Novartis Vaccines And Diagnostics, Inc. |
Cell culture medium for enhanced cell growth, culture longevity and product expression
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
ES2096590T3
(es)
|
1989-06-29 |
1997-03-16 |
Medarex Inc |
Reactivos biespecificos para la terapia del sida.
|
|
JP3039802B2
(ja)
*
|
1989-07-06 |
2000-05-08 |
ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア |
繊維芽細胞成長因子のための受容体
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5208020A
(en)
*
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
DE69132709T2
(de)
|
1990-06-29 |
2002-06-20 |
Large Scale Biology Corp., Vacaville |
Melaninproduktion durch transformierte mikroorganismen
|
|
US5122469A
(en)
*
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
|
US5508192A
(en)
|
1990-11-09 |
1996-04-16 |
Board Of Regents, The University Of Texas System |
Bacterial host strains for producing proteolytically sensitive polypeptides
|
|
US5264365A
(en)
*
|
1990-11-09 |
1993-11-23 |
Board Of Regents, The University Of Texas System |
Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
|
|
CA2405246A1
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with alterred binding properties
|
|
US5571894A
(en)
*
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
CN1068652A
(zh)
|
1991-06-10 |
1993-02-03 |
基斯通国际集团公司 |
监测再循环控制系统性能的方法和设备
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
|
AU665025B2
(en)
|
1991-09-23 |
1995-12-14 |
Cambridge Antibody Technology Limited |
Production of chimeric antibodies - a combinatorial approach
|
|
US5362852A
(en)
*
|
1991-09-27 |
1994-11-08 |
Pfizer Inc. |
Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
DE69232137T2
(de)
|
1991-11-25 |
2002-05-29 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
IL100219A0
(en)
|
1991-12-02 |
1992-09-06 |
Yeda Res & Dev |
Variable region within fibroblast growth factor receptors that confers ligand specificity
|
|
US5667988A
(en)
|
1992-01-27 |
1997-09-16 |
The Scripps Research Institute |
Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
|
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
|
EP0656064B1
(en)
|
1992-08-17 |
1997-03-05 |
Genentech, Inc. |
Bispecific immunoadhesins
|
|
MD1367C2
(ro)
|
1992-11-13 |
2000-11-30 |
Idec Pharmaceuticals Corporation |
Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
AU6446194A
(en)
|
1993-03-17 |
1994-10-11 |
Whittier Institute For Diabetes And Endocrinology, The |
Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US5910486A
(en)
|
1994-09-06 |
1999-06-08 |
Uab Research Foundation |
Methods for modulating protein function in cells using, intracellular antibody homologues
|
|
US5639635A
(en)
|
1994-11-03 |
1997-06-17 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US5712374A
(en)
*
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
DE69619526T2
(de)
|
1995-06-12 |
2002-10-31 |
Yeda Research And Development Co., Ltd. |
Fgf9 als spezifischer ligand für fgfr3
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
WO1997038123A1
(en)
*
|
1996-04-05 |
1997-10-16 |
Board Of Regents, The University Of Texas System |
Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
|
|
US5869245A
(en)
|
1996-06-05 |
1999-02-09 |
Fox Chase Cancer Center |
Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands
|
|
US5994071A
(en)
|
1997-04-04 |
1999-11-30 |
Albany Medical College |
Assessment of prostate cancer
|
|
US6083715A
(en)
|
1997-06-09 |
2000-07-04 |
Board Of Regents, The University Of Texas System |
Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
|
|
US6306591B1
(en)
*
|
1997-06-18 |
2001-10-23 |
Utah State University |
Screening for the molecular defect causing spider lamb syndrome in sheep
|
|
ATE296315T1
(de)
|
1997-06-24 |
2005-06-15 |
Genentech Inc |
Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
|
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
US6849255B2
(en)
*
|
1998-08-18 |
2005-02-01 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Methods and compositions for enhancing cartilage repair
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
IL128380A0
(en)
|
1999-02-04 |
2000-01-31 |
Yeda Res & Dev |
A method of screening for agonists and antagonists of FGFR
|
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
US7135311B1
(en)
*
|
1999-05-05 |
2006-11-14 |
Institut Curie |
Means for detecting and treating pathologies linked to FGFR3
|
|
CA2388245C
(en)
|
1999-10-19 |
2012-01-10 |
Kyowa Kirin Co., Ltd. |
The use of serum-free adapted rat cells for producing heterologous polypeptides
|
|
EP2180054A1
(en)
|
1999-12-24 |
2010-04-28 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
|
US7064191B2
(en)
*
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
IL139380A0
(en)
*
|
2000-10-31 |
2001-11-25 |
Prochon Biotech Ltd |
Active variants of fibroblast growth factor
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
CA2432257A1
(en)
|
2000-12-18 |
2002-06-27 |
Gene Logic, Inc. |
Treatment of bone disorders by modulation of fgfr3
|
|
US20040116330A1
(en)
*
|
2001-04-27 |
2004-06-17 |
Kenichiro Naito |
Preventive/therapeutic method for cancer
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
AU2002329540A1
(en)
|
2001-06-20 |
2003-01-02 |
Morphosys Ag |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
EP2180044A1
(en)
|
2001-08-03 |
2010-04-28 |
GlycArt Biotechnology AG |
Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
|
|
HUP0600342A3
(en)
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
|
EA200401325A1
(ru)
|
2002-04-09 |
2005-04-28 |
Киова Хакко Когио Ко., Лтд. |
Клетки с модифицированным геномом
|
|
CA2481920A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-containing medicament
|
|
US20040132140A1
(en)
*
|
2002-04-09 |
2004-07-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
|
US20040259150A1
(en)
|
2002-04-09 |
2004-12-23 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
|
|
JP4832719B2
(ja)
|
2002-04-09 |
2011-12-07 |
協和発酵キリン株式会社 |
ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
|
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
|
US7361740B2
(en)
*
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
EP3263596A1
(en)
|
2002-12-16 |
2018-01-03 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
DE602004022266D1
(de)
*
|
2003-03-26 |
2009-09-10 |
Progenika Biopharma Sa |
Lkarzinoms der blase
|
|
US8088387B2
(en)
*
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
IL156495A0
(en)
|
2003-06-17 |
2004-01-04 |
Prochon Biotech Ltd |
Use of fgfr3 antagonists for treating t cell mediated diseases
|
|
US20080241884A1
(en)
|
2003-10-08 |
2008-10-02 |
Kenya Shitara |
Fused Protein Composition
|
|
JPWO2005035778A1
(ja)
|
2003-10-09 |
2006-12-21 |
協和醗酵工業株式会社 |
α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
|
|
ES2672640T3
(es)
*
|
2003-11-05 |
2018-06-15 |
Roche Glycart Ag |
Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
|
|
US7498298B2
(en)
*
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
|
CA2550245A1
(en)
*
|
2003-12-19 |
2005-07-21 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
|
EP1773885B1
(en)
|
2004-08-05 |
2010-04-21 |
Genentech, Inc. |
Humanized anti-cmet antagonists
|
|
WO2006048877A2
(en)
|
2004-11-04 |
2006-05-11 |
Fibron Limited |
Treatment of b-cell malignancies with fgfr3 inhibitors
|
|
TW200902555A
(en)
*
|
2005-01-03 |
2009-01-16 |
Hoffmann La Roche |
Antibodies against IL-13 receptor alpha 1 and uses thereof
|
|
NZ563370A
(en)
|
2005-06-20 |
2010-10-29 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
|
BRPI0617863A2
(pt)
|
2005-10-28 |
2011-08-09 |
Irm Llc |
compostos e composições como inibidores da proteìna quinase
|
|
AU2007248444B2
(en)
|
2006-01-05 |
2012-10-25 |
Genentech, Inc. |
Anti-EphB4 antibodies and methods using same
|
|
EP2046384A4
(en)
*
|
2006-06-15 |
2009-12-02 |
Fibron Ltd |
ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
|
|
US8153764B2
(en)
|
2007-03-15 |
2012-04-10 |
Reverse Proteomics Research Institute Co., Ltd. |
Biomarker specific to brain/nerve or specific to neuronal differentiation
|
|
AU2008323206B2
(en)
|
2007-11-12 |
2014-08-14 |
U3 Pharma Gmbh |
AXL antibodies
|
|
UY31800A
(es)
|
2008-05-05 |
2009-11-10 |
Smithkline Beckman Corp |
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
|
|
US8187601B2
(en)
|
2008-07-01 |
2012-05-29 |
Aveo Pharmaceuticals, Inc. |
Fibroblast growth factor receptor 3 (FGFR3) binding proteins
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
AR073770A1
(es)
|
2008-10-20 |
2010-12-01 |
Imclone Llc |
Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
|
|
TWI507205B
(zh)
|
2009-03-25 |
2015-11-11 |
Genentech Inc |
抗ｆｇｆｒ３抗體及使用方法
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CA2878183A1
(en)
|
2012-07-27 |
2014-01-30 |
Genentech, Inc. |
Methods of treating fgfr3 related conditions
|
|
EP2743657B1
(en)
|
2012-12-13 |
2016-03-02 |
Thomson Licensing |
Method for controlling an image display device to allow an observer to perceive colours as another observer
|
|
CA2916681A1
(en)
|
2013-07-16 |
2015-01-22 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
|
TWI541022B
(zh)
|
2013-12-18 |
2016-07-11 |
應克隆公司 |
針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
|
|
JP6774421B2
(ja)
|
2015-02-19 |
2020-10-21 |
フュージョン ファーマシューティカルズ インク． |
がんの治療のための方法、組成物、及びキット
|
|
US10983340B2
(en)
|
2016-02-04 |
2021-04-20 |
Digilens Inc. |
Holographic waveguide optical tracker
|
|
SG11201906249PA
(en)
|
2017-02-06 |
2019-08-27 |
Rainier Therapeutics Inc |
Methods, compositions, and kits for treatment of cancer
|
|
US20200277387A1
(en)
|
2019-03-01 |
2020-09-03 |
Rainier Therapeutics, Inc. |
Methods and compositions for treating cancer
|